Drug delivery

Global Transdermal Drug Delivery Market, Technology and Competitive Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 29, 2021
Pharmaceutical, Health, Medical Supplies, Blood, Skin, Parkinson's disease, Drug delivery, Birth, Angina, Nanoparticle, Hormone replacement therapy, Lists of diseases, Smoking cessation, Pain, Pharmaceutical industry

The "Transdermal Drug Delivery - Technologies, Markets, and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Transdermal Drug Delivery - Technologies, Markets, and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • The market for transdermal drug delivery is analyzed according to technologies and therapeutic areas from 2020 to 2030.
  • This report deals with transdermal drug delivery - an approach used to deliver drugs through the skin for therapeutic use as an alternative to oral, intravascular, subcutaneous and transmucosal routes.
  • Various transdermal drug delivery technologies are described including the use of suitable formulations, carriers and penetration enhancers.

Paper & Paperboard Packaging Market worth $254.5 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, November 29, 2021
Knowledge, FBB, DS Smith, Personal, Plastic, Industry, Mondi, Glass, Income, CAGR, Region, Drug delivery, WLC, Health, USD, Amcor, GEM, SME, Paper, WestRock, Research, Metal, International Paper, Food, Lists of countries and territories, Growth, Whelping box, Plastic bottle, CUK, Content, Intelligence, SBS, Recycling, Cardboard, Marketing

The rising demand for sustainable and recycled packaging for food, healthcare, and personal & homecare applications will further drive the paper & paperboard packaging market.

Key Points: 
  • The rising demand for sustainable and recycled packaging for food, healthcare, and personal & homecare applications will further drive the paper & paperboard packaging market.
  • View Detailed Table of Content Here: https://www.marketsandmarkets.com/Market-Reports/paper-paperboard-packag...
    Food is expected to be the fastest-growing application in the Paper & paperboard packaging market during the forecast period.
  • It accounted for a share of about 42.2% of the paper & paperboard packaging market, in terms of value, in 2020.
  • APAC is expected to hold the largest market share in the global Paper & paperboard packaging market during the forecast period.

Global Drug Delivery Companies Compendium 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 24, 2021
Pharmaceutical, Health, Transport, Logistics, Supply Chain Management, Compendium, Drug delivery, Drug development, Directory, Intelligence, Dietary supplement, Medical device

The "Drug Delivery Companies Compendium 2021" directory has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Drug Delivery Companies Compendium 2021" directory has been added to ResearchAndMarkets.com's offering.
  • The Drug Delivery Companies Compendium is a cost-effective, time saving product that answers all of your questions about the Drug Delivery companies worldwide.
  • Whether you are investing in drug delivery technologies R&D, selecting the right drug delivery system for your R&D products, or searching for the best licensing partner, the Drug Delivery Companies Compendium is for you
    Powerful drug development intelligence you can rely on.
  • This Compendium contains in-depth reference source information on the top players in drug delivery, their major technology platforms, and their strategic alliances.

Global Drug Delivery Deals Directory, 2014-2021 | 1,500+ Deals Available by Company A-Z, Headline Value, Stage of Development at Signing, Deal Component Type, Specific Therapy Target, Technology Type - ResearchAndMarkets.com

Retrieved on: 
Monday, November 22, 2021
Health, Pharmaceutical, Chapter Three, Review, U.S. Securities and Exchange Commission, Mecum Dealmakers, Agreement, Drug delivery, It Takes Two, Chapter One, Confidentiality, SEC, Chapter Four, A-Z, Record, Securities & Exchange Commission of Pakistan, Hyperlink, Research, Orientation, Chapter Six, Ownership, Chapter Five, Intellectual property, Cryptocurrency, Pharmaceutical industry, Risk management, Bookkeeping, Publishing, Fine chemical, Birth control, Lease, Petroleum, Property management, Practice of law

The Global Drug Delivery Partnering Terms and Agreements 2014-2021 report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.

Key Points: 
  • The Global Drug Delivery Partnering Terms and Agreements 2014-2021 report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.
  • A comprehensive series of appendices is provided organized by Drug Delivery partnering company A-Z, stage of development, deal type, and therapy focus.
  • The Global Drug Delivery Partnering Terms and Agreements 2014-2021 report provides comprehensive access to available deals and contract documents for over 1500 Drug Delivery deals.
  • Global Drug Delivery Partnering Terms and Agreements 2014-2021 provides the reader with the following key benefits:
    Insight into terms included in a Drug Delivery partnering agreement, with real world examples

Global Transdermal Drug Delivery Market to Reach $7.4 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 1, 2021
Pharmaceutical, Health, Cardiology, Medical Devices, CAGR, CNS, Growth, COVID-19, Drug delivery, Transdermal patch, Pet

The "Transdermal Drug Delivery - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Transdermal Drug Delivery - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Transdermal Drug Delivery, estimated at US$4.9 Billion in the year 2020, is projected to reach a revised size of US$7.4 Billion by 2027, growing at a CAGR of 6.1% over the analysis period 2020-2027.
  • The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 5.7% CAGR
    The Transdermal Drug Delivery market in the U.S. is estimated at US$1.4 Billion in the year 2020.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$854.6 Million by the year 2027.

TriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of SD-101 via Pressure-Enabled Drug Delivery in Uveal Melanoma Liver Metastases

Retrieved on: 
Tuesday, September 7, 2021
Biotechnology, Pharmaceutical, Optical, Oncology, General Health, Health, Hospitals, Clinical Trials, the TriNav Infusion System, TriSalus, THE TRINAV INFUSION SYSTEM, TRISALUS

This study is designed to evaluate the intravascular administration of SD-101 into uveal melanoma liver metastasis lesions in combination with checkpoint inhibitors using the novel Pressure-Enable Drug Delivery (PEDD) approach.

Key Points: 
  • This study is designed to evaluate the intravascular administration of SD-101 into uveal melanoma liver metastasis lesions in combination with checkpoint inhibitors using the novel Pressure-Enable Drug Delivery (PEDD) approach.
  • Uveal melanoma is considered an ultra-rare cancer, affecting about 2,500 people in the U.S. every year.
  • Despite this, the disease is the most common primary eye tumor in adults and the second most common form of melanoma.
  • TriSalus Life Sciences is an emerging immuno-oncology company dedicated to developing immunotherapy treatments for liver and pancreatic tumors using novel delivery technologies to improve patient outcomes.

Progenity Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, August 12, 2021
DDS, Trial of the century, Result, Analysis, NPV, IV, CEO, IBD, Liraglutide, Ulcerative colitis, Pre-eclampsia, Inflammatory bowel disease, Disease, Private Securities Litigation Reform Act, GLP, Adalimumab, COVID-19, Program, Precision medicine, Partnership, GLOBE, SEC, Research, Doctor of Philosophy, Webcast, Animal, Patient, Health, Drug delivery, Genomics, Proteomics, Financial condition report, Comparison, Metabolomics, Nasdaq, Epigenomics, Enema, Review, Pharmaceutical industry, Cryptocurrency, Reinsurance

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics, today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

Key Points: 
  • Management will host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT
    SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics, today provided a corporate update andreported financial results for the second quarter ended June 30, 2021.
  • In June 2021, raised approximately $40.0 million in gross proceeds from a private placement with two leading healthcare-focused investment funds.
  • Progenity will host a webcast and conference call to discuss the second quarter financial results and answer investment community questions today, Thursday, August 12, 2021 at 4:30 p.m.
  • Progenity expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Ground-breaking Technology by Micellae, a University of Toronto Spinout, Set to Revolutionize Cannabinoid Delivery

Retrieved on: 
Wednesday, August 4, 2021
Health sciences, Life sciences, Pharmacology, Dosage forms, Pharmaceutical industry, Excipient, Pharmacy, Drug delivery, Self-microemulsifying drug delivery system, Bioavailability

TORONTO, Aug. 4, 2021 /PRNewswire/ -Micellae Delivery Systems Inc. ("Micellae") today announced the launch of its breakthrough drug delivery technology, O2W, the fastest oral bioavailability-enhancing formulation.

Key Points: 
  • TORONTO, Aug. 4, 2021 /PRNewswire/ -Micellae Delivery Systems Inc. ("Micellae") today announced the launch of its breakthrough drug delivery technology, O2W, the fastest oral bioavailability-enhancing formulation.
  • University of Toronto (U of T) Researcher and Micellae's Founder and CEO, Dr. Mehdi Nouraei, highlighted that,"Emulsification technologies have previously been employed in cannabinoid-based products.
  • However, existing technologies are less than optimal and result in significant compromises, including slow onset of action, complex manufacturing, unpleasant taste, and short shelf-life.
  • O2W is the only self-dispersing and fully water-dilutable Self-Microemulsifying Drug Delivery System (SMEDDS) made with food-grade excipients.

IntelGenX to Report Second Quarter 2021 Financial Results on August 4, 2021 – Conference Call to Follow

Retrieved on: 
Thursday, July 29, 2021
Communication, Forward-looking statement, Transdermal, Drug delivery

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

Key Points: 
  • IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.
  • IntelGenxs superior film technologies, including VersaFilm, VetaFilm and transdermal, allow for next generation pharmaceutical products that address unmet medical needs.
  • This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties.
  • Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward-looking statements.

$158 Billion Drug Delivery Systems (DDS) Markets - Global Forecast to 2027 - Necessity of Drug Delivery Systems for Enhancing Therapeutic Efficiency and Safety Profile of Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021
Health, Pharmaceutical, Health sciences, Health, Pharmaceuticals policy, Drug delivery, Medical equipment, Pharmacovigilance, Pharmaceutical industry, Drug

The "Drug Delivery Systems (DDS) Global Market - Forecast To 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Drug Delivery Systems (DDS) Global Market - Forecast To 2027" report has been added to ResearchAndMarkets.com's offering.
  • Global drug delivery systems market is expected to reach $158,006.4 million by 2027 growing at a mid single digit CAGR from 2020 to 2027 due to escalating necessity of targeted and controlled drug delivery systems to increase the therapeutic efficiency and safety profile of medications.
  • The top five pharmaceutical players occupy majority of the market share and the remaining minority share of the market is occupied by other players.
  • The drug delivery system enhanced product providers market is consolidated with the top five pharmaceutical players occupying 60.9% of the market share and the remaining 39.1% of the market being occupied by other players.